Depression is a comorbidity affecting quality of life (QoL) in patients with Parkinson's disease (PD) and requires appropriate treatment. This study evaluated the tolerability, safety, and efficacy of duloxetine 60 mg once daily for 12 weeks in PD patients with major depressive disorder (MDD). Research and design methods: Non-comparative, open-label, multi-center study.
Bonuccelli, U., Meco, G., Fabbrini, G., Tessitore, A., Pierantozzi, M., Stocchi, F., et al. (2012). A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. EXPERT OPINION ON PHARMACOTHERAPY, 13(16), 2269-2280 [10.1517/14656566.2012.736490].
A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease
PIERANTOZZI, MARIANGELA;CALTAGIRONE, CARLO;
2012-11-01
Abstract
Depression is a comorbidity affecting quality of life (QoL) in patients with Parkinson's disease (PD) and requires appropriate treatment. This study evaluated the tolerability, safety, and efficacy of duloxetine 60 mg once daily for 12 weeks in PD patients with major depressive disorder (MDD). Research and design methods: Non-comparative, open-label, multi-center study.| File | Dimensione | Formato | |
|---|---|---|---|
|
ExpOpin.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
544.93 kB
Formato
Adobe PDF
|
544.93 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
ExpOpin.pdf
accesso aperto
Licenza:
Non specificato
Dimensione
544.93 kB
Formato
Adobe PDF
|
544.93 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
